Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

October 15, 2027

Study Completion Date

October 15, 2027

Conditions
Gastric Cancer
Interventions
DRUG

Irinotecan Hydrochloride Liposome Injection

At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.

Trial Locations (1)

710061

First Affiliated Hospital of Xian Jiaotong University, Xi'an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT06499610 - Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter